New Mouth Cancer Test Promises 1-Hour Results, Could Cut Unnecessary Biopsies by 90%
Researchers at Queen Mary University of London have developed a novel molecular test, qMIDS-V3, capable of detecting oral squamous cell carcinoma with high accuracy in under an hour. This innovative test, described in Nature Biomarker Research, utilizes a simple oral brushing technique to analyze the expression of four genes associated with oral cancer. Unlike traditional histopathology, which can take weeks and requires specialized pathologists, qMIDS-V3 delivers results in approximately 60 minutes using equipment similar to that for COVID PCR tests. This advancement holds the potential to eliminate over 90% of unnecessary invasive biopsies for patients with low-risk oral lesions. The test is designed for accessibility, functioning effectively in resource-limited settings with stable sample materials that do not require cold chain transport and have a low cost of less than ten US dollars per sample. A commercial partner is being sought to bring the test to clinical practice within two years. The study involved 1,090 brush biopsies from 545 patients, demonstrating a global accuracy of 95.5%, with a sensitivity of 95.7% and specificity of 95.1%. The qMIDS-V3 aims to resolve the challenge where most oral lesions are benign, yet many patients undergo painful and potentially infection-prone surgical biopsies. It provides a quantitative, non-invasive method to stratify risk, guiding biopsies only to those who truly need them and allowing for safe, repeated non-invasive monitoring of low-risk lesions, thereby reducing patient anxiety and optimizing healthcare resources.
This molecular diagnostic test represents a significant potential shift in oral cancer screening by offering rapid, non-invasive risk stratification. By leveraging existing PCR infrastructure and low-cost materials, the qMIDS-V3 technology addresses critical healthcare access and efficiency challenges, particularly in resource-constrained environments. Its development could fundamentally alter the diagnostic pathway for suspicious oral lesions, moving from a predominantly invasive biopsy-first approach to a risk-guided, minimally invasive strategy. This system-level change has the potential to reduce healthcare costs, improve patient experience by minimizing unnecessary procedures, and enable more proactive surveillance. The key challenge ahead will be successful commercialization and integration into clinical workflows, ensuring equitable access and robust validation across diverse patient populations and healthcare systems globally.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.